学术详细服务对2型糖尿病处方与诊疗的有效性
该研究基于加拿大安大略省卫生行政数据库,采用匹配队列设计,比较接受学术详细(AD)的全科医生与未接受者的2型糖尿病处方与诊疗模式。结果显示AD组生物类似胰岛素、SGLT2抑制剂或GLP-1受体激动剂的使用改善更明显,但二甲双胍使用者维生素B12检测和血糖控制(A1C<8%)无显著差异。
要点
- AD组生物类似胰岛素使用月度增幅更大(9.0% vs 5.6%)。
- AD组SGLT2抑制剂或GLP-1受体激动剂使用率更高(40.1% vs 31.5%)。
- A1C控制(<8%)两组相似(约80%),B12检测无显著时间×组差异。
核心结论
- 学术详细(AD)可改善2型糖尿病处方质量,但未显著改变B12检测和血糖控制。
研究设计与样本
- 基于加拿大安大略省卫生行政数据库的人群匹配队列研究。
- 纳入2020年9月至2022年9月有活跃计费的初级保健医生,每位AD医生按指数年份、地区、性别、执业年限和糖尿病患者比例匹配最多4名对照。
主要发现
- AD组372名医生,对照组1450名医生,人口学特征均衡。
- 基线时AD组患者数较少(1292 vs 1526),但每患者预约次数更多(4.2 vs 3.0)。
- 干预后AD组生物类似胰岛素使用月度增幅更大(9.0% vs 5.6%)。
- AD组二甲双胍使用者B12检测率更高(76.5% vs 60.0%),SGLT2抑制剂或GLP-1受体激动剂使用率更高(40.1% vs 31.5%)。
- A1C控制(<8%)两组相似(约80%);除B12检测(P=0.790)和A1C(P=0.815)外,所有结局的时间×组差异显著(P<0.001)。
关键数值与推荐
- AD组生物类似胰岛素使用月度增幅9.0%,对照组5.6%。
- AD组SGLT2抑制剂或GLP-1受体激动剂使用率40.1%,对照组31.5%。
- AD组二甲双胍使用者B12检测率76.5%,对照组60.0%。
- A1C<8%的比例两组均约80%。
- 时间×组差异:除B12检测(P=0.790)和A1C(P=0.815)外,其余结局P<0.001。
临床怎么用
- 全科医生可参与学术详细项目以优化2型糖尿病处方,如增加生物类似胰岛素和SGLT2抑制剂/GLP-1受体激动剂的使用。
- AD对B12检测和血糖控制影响有限,仍需常规监测这些指标。
局限性
- 观察性设计可能残留混杂。
- 仅基于安大略省行政数据,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Academic detailing (AD), a one-on-one evidence-based educational outreach strategy for healthcare providers, has been effective in improving prescribing behavior. However, its impact on diabetes care outcomes in Canada remains underexplored. OBJECTIVE: We aimed to compare prescribing and care patterns for type 2 diabetes between physicians who received AD and those who did not. METHODS: We conducted a population-based matched cohort study in Ontario, Canada, using health administrative databases. We included primary care physicians with active billing from September 2020 to September 2022. Each AD physician was matched to a maximum four controls based on index year, region, sex, years in practice, and proportion of patients with diabetes. We assessed monthly clinical outcomes for 12 months pre and 18 months postintervention using mixed-effects models. RESULTS: The cohort included 372 AD and 1450 control physicians, with balanced demographics. At baseline, AD physicians saw fewer patients (1292 vs. 1526) but delivered more appointments per patient (4.2 vs. 3.0). Both groups had 15% of patients with diabetes. Post-intervention, biosimilar insulin use increased more sharply in the AD group (9.0% vs. 5.6% monthly). AD physicians consistently had higher B12 testing among metformin users (76.5% vs. 60.0%) and greater use of SGLT2 inhibitors or GLP-1 receptor agonists (40.1% vs. 31.5%). A1C control (<8%) remained similar across groups (∼80%). Time × group differences were significant for all outcomes (P < 0.001) except B12 testing (P = 0.790) and A1C levels (P = 0.815). CONCLUSIONS: The AD group saw greater improvements in diabetes prescribing post-intervention. Engaging physicians in AD could enhance diabetes care quality. Academic detailing (AD) is a one-on-one educational approach for healthcare providers. Little is known about the effects of AD on diabetes care in Canada. This study compared the care patterns of family doctors who received AD with similar doctors who did not receive AD, using health administrative data from Ontario, Canada. The results showed that AD doctors saw fewer patients but provided more appointments per patient compared to similar doctors who did not receive AD. After the AD intervention, the AD group prescribed more biosimilar insulins, SGLT2 inhibitors, and GLP-1 receptor agonists compared to the control group. No changes were found for vitamin B12 testing among patients on metformin and blood sugar control (measured by A1C levels). In conclusion, we found that AD improved prescribing outcomes among diabetes patients. Efforts should be made to maximize the engagement of family doctors in the program.
引用
- Chu C, Ghahramani D, Rawn T, et al. Effectiveness of an academic detailing service to support appropriate prescribing and care in patients with type 2 diabetes. Fam Pract. 2025. PMID: 41510816. doi:10.1093/fampra/cmaf101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。